Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
23.60
+1.43 (6.45%)
At close: Mar 9, 2026, 4:00 PM EDT
23.54
-0.06 (-0.25%)
After-hours: Mar 9, 2026, 5:14 PM EDT
Neurogene Employees
Neurogene had 107 employees as of December 31, 2024. The number of employees increased by 16 or 17.58% compared to the previous year.
Employees
107
Change (1Y)
16
Growth (1Y)
17.58%
Revenue / Employee
n/a
Profits / Employee
-$795,607
Market Cap
365.56M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 107 | 16 | 17.58% |
| Dec 31, 2023 | 91 | 9 | 10.98% |
| Dec 31, 2022 | 82 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 305 |
| Absci | 157 |
| X4 Pharmaceuticals | 143 |
| Adlai Nortye | 123 |
| Foghorn Therapeutics | 112 |
| Aura Biosciences | 109 |
| Immuneering | 54 |
| Candel Therapeutics | 38 |
NGNE News
- 6 days ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 11 days ago - Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome - Business Wire
- 4 weeks ago - Neurogene to Participate in Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome - Business Wire
- 2 months ago - Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 3 months ago - Neurogene: From Speculation To Execution With NGN-401 - Seeking Alpha
- 4 months ago - Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates - Business Wire